Tracking the continuing evolution of a devastating virus
COVID-19 remains a real threat to public health. Since the beginning of the pandemic, the number of U.S. cases is now over 90 million and climbing, with deaths totaling over 1 million.1
While vaccines and social distancing measures have helped combat worsening effects of the virus, as of late 2022, the FDA has yet to approve any therapeutic that improves time to clinical recovery for outpatients.
New variants of the virus are expected to occur. As both the variance and prevalence of COVID-19 continues to evolve, so does 60° Pharmaceuticals (60P).
By utilizing resources and a strong clinical pipeline, 60P remains committed to finding potential therapeutic solutions to help the infected population.*
*ARAKODA has not been reviewed or approved by the U.S. Food and Drug Administration for the treatment or prevention of COVID-19, babesiosis, or fungal diseases.
Reference: 1. Centers for Disease Control and Prevention. COVID Data Tracker. Updated August 11, 2022. https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed August 15, 2022.